Exelixis | EXEL - Net Income


Exelixis reported $193.58M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 273.57M 201.79M Dec/2025
Agios Pharmaceuticals USD -108.04M 4.61M Dec/2025
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
Amgen USD 1.33B 1.88B Dec/2025
AstraZeneca USD 2.33B 207M Dec/2025
Bayer EUR -3.76B 2.79B Dec/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Cytokinetics USD -183.03M 123.15M Dec/2025
Eisai JPY 17.18B 7.02B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
Exelixis USD 193.58M 8.73M Sep/2025
Genmab DKK 31M 370M Dec/2025
Glaxosmithkline GBP 846.06M 1.87B Dec/2025
Incyte USD 299.28M 124.89M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
MacroGenics USD -14.16M 30.98M Dec/2025
Merck USD 2.96B 2.82B Dec/2025
Moderna USD -200M 625M Sep/2025
Nektar Therapeutics USD -36.08M 978K Dec/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novartis USD 2.41B 1.52B Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sanofi EUR -801M 3.6B Dec/2025
Takeda JPY 103.64B 115.44B Dec/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Xencor USD -6.65M 626K Dec/2025